Department of Microbiology and Infectious Diseases, Snyder Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
J Immunol. 2011 Jun 15;186(12):6798-806. doi: 10.4049/jimmunol.1004222. Epub 2011 May 18.
Adenosine has been established as an important regulator of immune activation. It signals through P1 adenosine receptors to suppress activation of T cells and professional APCs. Adenosine deaminase (ADA) counters this effect by catabolizing adenosine. This regulatory mechanism has not been tested in a disease model in vivo. Questions also remain as to which cell types are most sensitive to this regulation and whether its dysregulation contributes to any autoimmune conditions. We approached this issue using the NOD model. We report that ADA is upregulated in NOD dendritic cells, which results in their exuberant and spontaneous activation. This, in turn, triggers autoimmune T cell activation. NOD DCs deficient in ADA expression have a greatly reduced capacity to trigger type I diabetes. We also provide evidence that although many cell types, particularly T cells, have been implicated as the suppression targets by adenosine in an in vitro setting, DCs also seem to be affected by this regulatory mechanism. Therefore, this report illustrates a role of ADA in autoimmunity and suggests a potential target for therapeutic intervention.
腺苷已被确定为免疫激活的重要调节剂。它通过 P1 腺苷受体发出信号,抑制 T 细胞和专业 APC 的激活。腺苷脱氨酶 (ADA) 通过分解腺苷来对抗这种作用。这种调节机制尚未在体内疾病模型中进行测试。目前仍存在一些问题,例如哪些细胞类型对这种调节最敏感,以及其失调是否会导致任何自身免疫性疾病。我们使用 NOD 模型来解决这个问题。我们报告称,ADA 在 NOD 树突状细胞中上调,导致其过度和自发激活。这反过来又触发了自身免疫性 T 细胞的激活。ADA 表达缺陷的 NOD DC 触发 I 型糖尿病的能力大大降低。我们还提供了证据表明,尽管在体外环境中,许多细胞类型,特别是 T 细胞,被认为是腺苷的抑制靶标,但 DC 似乎也受到这种调节机制的影响。因此,本报告说明了 ADA 在自身免疫中的作用,并提出了一个治疗干预的潜在靶点。